english.prescrire.org > Spotlight > 100 most recent > Risankizumab (Skyrizi°) in Crohn's disease after failure of at least one other immunosuppressant

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Risankizumab (Skyrizi°) in Crohn's disease after failure of at least one other immunosuppressant

 Marketing Authorisations   When a corticosteroid and "conventional" immunosuppressive treatments such as azathioprine are unsatisfactory in a patient with moderate to severe Crohn's disease, adalimumab (an anti-TNF-alpha monoclonal antibody) or ustekinumab (an anti-interleukin-12 and anti-interleukin-23 monoclonal antibody) are immunosuppressants of choice. The anti-interleukin-23 monoclonal antibody risankizumab has also been authorised for use in this situation, or when second-line immunosuppressants have failed.
Full article available for download by subscribers

 ©Prescrire 1 November 2024

Source: "Risankizumab (Skyrizi°) in Crohn's disease after failure of at least one other immunosuppressant" Prescrire Int 2024; 33 (264): 264. Subscribers only.

Enjoy full access to Prescrire International, and support independent information

 
Share
Share on Facebook Share on Twitter
 
See also:

"Ustekinumab in Crohn's
disease. No more effective
than adalimumab, but a few
differences in the frequency
of various adverse effects"
Prescrire Int 2024;
32 (250): 182.
Subscribers only

"Upadacitinib (Rinvoq°)
in Crohn's disease"
Prescrire Int 2024;